Canaccord Genuity Reiterates a 'Buy' Edwards Lifesciences (EW); Utilizing TAVI

Canaccord Genuity reiterates a 'Buy' Edwards Lifesciences (NYSE: EW) price target of $123.00 (from $103.00).

Analyst, Jason R. Mills, said, "The ACC, STS, and CMS hosted a webinar late last week on the TVT registry, to which TAVI centers must contribute per FDA & CMS requirements. Experts from these agencies highlighted earlier-than-expected progress, which we think could be a positive signal for TAVI utilization, as the registry is tied to reimbursement. We maintain our 2012 US SAPIEN estimates, but think upside is possible."

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $101.56 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project
• Benchmark Reiterates Buy Rating on NVIDIA (NVDA), Updates Estimates